Dr. GPCR’s Post

The precise immunological mechanisms involved in clinical responses to bispecific T-cell engagers (TCE) in multiple myeloma (MM) are poorly understood. In a detailed case report, Krzysiek et al. documented that complete response to elranatamab, a B-cell maturation antigen-CD3 bispecific TCE, was associated with clonal CD8+ T-cell expansion in penta-refractory MM. https://lnkd.in/e2kpyKF9

People with #HereditaryAgioedema (#HAE) have a personal choice of two distinct therapeutic strategies based on clinical assessment: treatment of attacks (on-demand) or prevention of attacks (prophylactic). Our goal is to develop novel, oral on-demand and prophylactic alternatives with #deucrictibant — the only oral B2 receptor antagonist currently in clinical development for the treatment of HAE to our knowledge. Visit our website to learn more about how our treatment strategy aims to improve the quality of life for people with HAE: https://lnkd.in/gzNk4GdP #ClinicalTrials #HAEtreatment

Timely webinar — I am prescribing this class fairly often for the right patient. Looking forward to hearing the successes and the challenges including real world side effects that are surfacing given the frequency of the prescriptions. Hope to “see” many of my colleagues in the webinar!

🔬 New high-level results from LAURA Phase III trial: Osimertinib improved PFS for patients with unresectable, Stage III EGFR mutated NSCLC after chemoradiotherapy. OS data is not mature but shows a favourable trend. #CancerResearch #ONCOalert #ONCOassist https://buff.ly/49xC1j6

ONE-GO biosensor platform: Using G protein-coupled receptors (GPCR) research enabling high fidelity measurement of G-protein activation across various cell types, including primary ones. This open-source tool unveils new insights into GPCR selectivity, antipsychotic pharmacogenomics, and signaling biases, revolutionizing our understanding of GPCR behavior in physiological and pathological states. #GPCR #biosensors #pharmacogenomics

Today is World Thrombosis Day, observed on 13th October to mark the birthday of Rudolf Virchow, a German pioneer of the pathophysiology of thrombosis. Thrombosis, commonly known as blood clots within vessels, contributes to 1 in 4 deaths worldwide and is a leading cause of cardiovascular death. This year’s theme urges everyone to Move Against Thrombosis, and raise awareness of risk factors, signs and symptoms. To learn more and support World Thrombosis Day, visit www.worldthrombosisday.org. Quadratech Diagnostics Ltd are committed to offering an extensive portfolio of diagnostic reagents for investigating coagulation pathways, haemophilia, thrombophilia, fibrinolysis and platelet function, alongside diagnostic tests for antithrombotic drug monitoring and thrombodynamics. To learn more, visit: https://lnkd.in/g9FsZhvr. #WTDay24 #worldthrombosisday #quadratechdiagnostics #ISTH #medicaldiagnostics #medicalsupplies #research

🟣 Assessing TCR Cβ1 in T Cell Malignancies Emerging evidence suggests that T cell malignancies exhibit abnormally high levels of TCR Cβ1 (𝗧𝗥𝗕𝗖𝟭), making it a promising therapeutic target for immunotherapies aimed at eliminating these aberrant T cells. Explore our diverse formats of clone 𝗝𝗢𝗩𝗜.𝟭 to identify T cells for potential downstream functional studies. Explore our 𝗝𝗢𝗩𝗜.𝟭 formats: https://lnkd.in/egQE96qg #jovi1 #trbc1 #tcells #clonality Gerardo Cruz , Ignacio Martin , Yoko Yano , Kenny Liu , Emilio Diaz , Sergio Eduardo Bustos Crisóstomo , Eva Zemlickova , Jean-Baptiste GUILLERME

🆕 Foundation for the Accreditation of Cellular Therapy (FACT) and Joint Accreditation Committee ISCT-Europe & The EBMT (JACIE) have published a preliminary draft of both: ☑️ FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration, Ninth Edition (HCT 9 Standards), and ☑️ FACT-JACIE International Standards for Immune Effector Cells, Third Edition (IEC) 💡 Read the news article and discover more details 🔗 https://lnkd.in/dduDrkmf The drafts are now open for public comments which will be accepted until 15 December 2024. 📅 As the field of #CellularTherapy is continuously evolving, the goal for each new edition of the Standards is to accurately capture and reflect those changes to remain a relevant and useful resource for programs. The comments, suggestions, and feedback solicited during the public comment period are not only welcome, but vital to ensuring that we achieve this goal. 🔬 ✔️

The #ASTROnews Spring issue is here! This issue highlights the emerging and reemerging nonmalignant indications of therapeutic radiation. https://ow.ly/t5Ch50RbNtK

Yesterday we announced the candidate nomination of our lead program targeting the melanocortin-2 (MC2) receptor, a GPCR for the adrenocorticotropic hormone (ACTH). The focus of our MC2 program has been to increase the receptor residency time to make OMass’ antagonists resistant to competition by the endogenous ligand. This can allow all patients suffering from conditions related to ACTH excess, including congenital adrenal hyperplasia and Cushing’s syndrome, to be treated. The nomination represents a key milestone for OMass as we progress our MC2 program towards the clinic. Read the full press release here: https://lnkd.in/e3_wSE8H Learn more about the potential of our MC2 program to treat Cushing’s disease and congenital adrenal hyperplasia in a blog by our CSO, Ali Jazayeri, here: https://lnkd.in/d79xqUxh #nomination #drugdiscovery #masspec #biotech #lifescience #innovation